Abstract:diagnosis of PTSD. Finally, I will discuss aspects of the various trials that point to how NAC may be most effectively employed clinically in combination with psychosocial interventions, and perhaps other pharmacological treatments. Abstract There has been a decline in new therapies for unipolar depression. Current pharmacological therapies are attributed to symptom remission in only 30% of individuals with unipolar depression. As such, there is a clear need for the development of new therapies, instigated by investigators rather than reliance on pharmaceutical companies. There have been significant advancements in the understanding of the underlying pathophysiology of unipolar depression. Significant evidence is available to suggest that unipolar depression is mediated by inflammation. This is demonstrated by the induction of depressive symptoms fol-lowing pro-inflammatory treatment (e.g. interferon in hep-atitis-C) and more importantly, by alterations in peripheral cytokine levels in individuals with unipolar depression. Given this, we planned to trial a treatment specifically targeting inflammation as an adjunct to usual for individuals with mod-erate-severe unipolar depression. The agent selected is minocycline, a tetracycline antibiotic which has also been shown to inhibit microglial activation and also reduce oxidative stress, augment glutamate pathways and promote neuronal growth. This agent is of particular interest as in addition to increased inflammation, depression is also characterized by increased oxidative stress, altered glutamate function and decreased levels of neuronal growth factors (e.g. BDNF). We have completed a pilot double-blind placebo controlled trial of 200 mg/ day of minocycline as an adjunct to treatment as usual. The study includes 12 weeks of treatment followed by a follow-up visit 4 weeks later. The primary outcome measure for the study is the Montgomery Asberg Depression Rating Scale and a variety of clinical impression, functioning and quality of life scales are also included as secondary outcomes. The last study visit will be completed in December 2015 and trial results will be available in early 2016 to determine the preliminary efficacy of minocycline as an adjunctive therapy for moderate to severe unipolar depression. Abstract With depressive disorders the leading source of disability glob-ally, the identification of new targets for prevention and man-agement is imperative. A rapidly emerging field of research suggests that the microbiome-brain axis is of substantial rel-evance to mood and behavior. Similarly, unhealthy diet has recently emerged as a significant correlate of and risk factor for depression. This review provides evidence for the gut microbiota as a key factor mediating the link between diet and depressive illness and focuses on the potential of gut-focused interventions for the prevention and treatment of mood disorders. Recent findings: The development of new technologies is afford-ing a better understanding of how diet influences gut microbiota composition and activity and how this may, in turn, influence depressive illness. New evidence is also pointing to the possible utility of pre and probiotic formulations and fermented food in influencing mental health. Summary: Although in its early stages, the emerging field of research focused on the human microbiome suggests an impor-tant role for the gut microbiota in influencing brain development, behavior and mood in humans. The recognition that the gut microbiota interacts bi-directionally with other environmen-tal risk factors, such as diet and stress, suggests promise in the development of interventions targeting the gut microbiota for the prevention and treatment of common mental health disorders. Abstract Introduction: Depression in bipolar disorder is complex to treat, with few efficacious agents. Bipolar disorder thus is a significant burden on individuals, caregivers and the broader community. Current treatments are generally more effective against manic than depressive symptoms. The current study capitalises on recent evidence that alterations in mitochondrial function occur in bipolar disorder. Since there are many agents that have actions on mitochondrial bioenergetics, that this may be a druggable target. Methods: This was a 3 arm 16-week study which aimed to explore the potential effects of placebo,

Mitochondrial modulators in the treatment of bipolar depression: a systematic review and meta-analysis

A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials

Evaluating the Effect of Coenzyme Q10 Augmentation on Treatment of Bipolar Depression: A Double-Blind Controlled Clinical Trial

Adjunctive antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis

Targeting Inflammatory-Mitochondrial Response in Major Depression: Current Evidence and Further Challenges

Mitochondrial Dysfunction in the Pathophysiology of Bipolar Disorder: Effects of Pharmacotherapy

Minocycline As an Adjunctive Therapy for Unipolar Depression

Multi-trial, aggregated, individual participant data mega-analysis of short-term antidepressant versus mood stabilizer monotherapy of bipolar type II major depressive episode

Efficacy and acceptability of anti-inflammatory agents in major depressive disorder: a systematic review and meta-analysis

Comparative efficacy, safety, and tolerability of pharmacotherapies for acute mania in adults: a systematic review and network meta-analysis of randomized controlled trials

Mitochondrial Dysfunction as a Biomarker of Illness State in Bipolar Disorder: A Critical Review

Mitochondria in depression: The dysfunction of mitochondrial energy metabolism and quality control systems

Depression, mitochondrial bioenergetics, and electroconvulsive therapy: a new approach towards personalized medicine in psychiatric treatment - a short review and current perspective

Pharmacological mechanism of natural antidepressants: The role of mitochondrial quality control

Mindfulness-based Cognitive Therapy for Bipolar Disorder: A Systematic Review and Meta-Analysis

Metabolic regulation to treat bipolar depression: mechanisms and targeting by trimetazidine

Mitochondrial DNA oxidation, methylation, and copy number alterations in major and bipolar depression

Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review

Efficacy and tolerability of minocycline in depressive patients with or without treatment-resistant: a meta-analysis of randomized controlled trials

Lithium bidirectionally regulates depression- and mania-related brain functional alterations without worsening cognitive function in patients with bipolar disorder

Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis